PREMIUM
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial Infarction (PREMIUM)
Patient / Population Intervention / Exposition Vergleich Endpunkt
In 2,268 patients with STEMI undergoing primary PCI, aspirin-free prasugrel monotherapy was compared with 12 months of dual antiplatelet therapy on death, myocardial infarction or stroke at 12 months.
N
2.268
Design
Investigator-initiated, multicentre, open-label randomised controlled trial in Japan; 1:1 randomisation before primary PCI; all patients receive platinum-chromium everolimus-eluting stents (SYNERGY) with routine intravascular imaging guidance; non-inferiority design for the primary endpoint; 12-month follow-up
Endpunkt
Composite of all-cause death, myocardial infarction or stroke at 12 months (non-inferiority)